Journal of Immunotherapy Applications

Journal of Immunotherapy Applications

ISSN 2055-2394
Short report

A controversy on HLA-G and B-cell malignancies?

Edgardo D. Carosella1* and Vera Rebmann2

*Correspondence: Edgardo D. Carosella Edgardo.carosella@cea.fr

1. Institute of Emerging Diseases and Innovative Therapies (iMETI), Research Division in Hematology and Immunology (SRHI), Saint-Louis Hospital, University Paris Diderot, Paris, France.

Author Affiliations

2. Institute for Transfusion Medicine, University Hospital Essen, Virchowstr. 179, 45147 Essen, Germany.

Abstract

In solid tumors HLA-G is a clear immune-escape molecule inhibiting innate and adaptive effectors. This is not systematically demonstrated for B-cell malignancies, leading to a confused overall role for HLA-G in cancer likely due to the fact that malignant B-cells are as much of immune origin as the anti-tumoral effectors themselves.

Keywords: HLA-G, CLL, immune-escape, ILT2, cancer, B-cell malignancy, multiple myeloma

ISSN 2055-2394
Volume 3
Abstract Download